Have a feature idea you'd love to see implemented?
Let us know!
DRRX Durect Corp
Price (delayed)
$1.3
Market cap
$40.35M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.49
Enterprise value
$40.77M
DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic
Highlights
The EPS has soared by 68% year-on-year and by 41% since the previous quarter
The net income has soared by 56% YoY and by 32% from the previous quarter
Durect's gross profit has shrunk by 62% YoY
The revenue has dropped by 57% year-on-year
Key stats
What are the main financial stats of DRRX
Market
Valuations
Earnings
Shares outstanding
31.04M
Market cap
$40.35M
Enterprise value
$40.77M
Price to earnings (P/E)
N/A
Price to book (P/B)
8.01
Price to sales (P/S)
4.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.85
Revenue
$8.41M
EBIT
-$13.51M
EBITDA
-$13.51M
Free cash flow
-$26.17M
Per share
Balance sheet
Liquidity
EPS
-$0.49
Free cash flow per share
-$0.84
Book value per share
$0.16
Revenue per share
$0.27
TBVPS
$0.76
Total assets
$29.85M
Total liabilities
$24.82M
Debt
$16.06M
Equity
$5.04M
Working capital
-$1.98M
Debt to equity
3.19
Current ratio
0.91
Quick ratio
0.76
Net debt/EBITDA
-0.03
Margins
Efficiency
Dividend
EBITDA margin
-160.6%
Gross margin
80.8%
Net margin
-187.8%
Operating margin
-296.4%
Return on assets
-38.1%
Return on equity
-148.6%
Return on invested capital
-778.2%
Return on capital employed
-170.4%
Return on sales
-160.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DRRX stock price
How has the Durect stock price performed over time
Intraday
0%
1 week
2.36%
1 month
-13.91%
1 year
-48.62%
YTD
120.34%
QTD
-2.99%
Financial performance
How have Durect's revenue and profit performed over time
Revenue
$8.41M
Gross profit
$6.8M
Operating income
-$24.93M
Net income
-$15.8M
Gross margin
80.8%
Net margin
-187.8%
DRRX's operating margin has shrunk by 66% YoY but it is up by 22% QoQ
Durect's gross profit has shrunk by 62% YoY
The revenue has dropped by 57% year-on-year
The net income has soared by 56% YoY and by 32% from the previous quarter
Growth
What is Durect's growth rate over time
Valuation
What is Durect stock price valuation
P/E
N/A
P/B
8.01
P/S
4.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.85
The EPS has soared by 68% year-on-year and by 41% since the previous quarter
DRRX's P/B is 74% above its last 4 quarters average of 4.6 but 8% below its 5-year quarterly average of 8.7
Durect's equity has decreased by 39% from the previous quarter and by 8% YoY
The price to sales (P/S) is 62% lower than the 5-year quarterly average of 12.6 but 4.3% higher than the last 4 quarters average of 4.6
The revenue has dropped by 57% year-on-year
Efficiency
How efficient is Durect business performance
Durect's return on invested capital has surged by 55% YoY
Durect's ROA has increased by 38% YoY and by 24% from the previous quarter
The ROS is up by 35% since the previous quarter and by 6% year-on-year
Durect's ROE has increased by 31% from the previous quarter and by 17% YoY
Dividends
What is DRRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DRRX.
Financial health
How did Durect financials performed over time
The total assets is 20% more than the total liabilities
DRRX's total liabilities is down by 42% YoY and by 11% QoQ
The total assets has contracted by 39% YoY and by 18% from the previous quarter
The debt to equity is up by 44% since the previous quarter but it is down by 23% year-on-year
Durect's equity has decreased by 39% from the previous quarter and by 8% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.